CyberArk , the global leader in identity security, announced its 2025 Identity Security Impact Customer Award winners at the company's annual flagship conference, CyberArk IMPACT ?25, held in Boston.

By the time doctors got him hooked up to an EKG machine, everything looked fine ... Doctors performed another operation, a cryoablation, a procedure that freezes heart tissue responsible for ...

You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies ...

Conclusion: Only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of 94%, a complication rate of 0%, and a 100% treatment tolerance. 94% of patients were very ...

Adagio’s vCLAS TM Cryoablation System, which is currently the subject of an Investigational Device Exemption ("IDE") study called FULCRUM-VT, is a purpose-built system using the Company’s ...

Under the program, the FDA will provide Adagio with priority review and interactive communication during the vCLAS TM Cryoablation System premarket review phase. VT is a rapid, abnormal heart ...

The vCLASTM Cryoablation System, which leverages Adagio’s proprietary Ultra-Low Temperature Cryoablation (ULTC) technology, is currently undergoing a study under an Investigational Device ...

Adagio’s vCLAS TM Cryoablation System, which is currently the subject of an Investigational Device Exemption ("IDE") study called FULCRUM-VT, is a purpose-built system using the Company’s proprietary ...